Trellis Bioscience, Inc.

Contrafect Corporation

Ibio Limited

Angeles Estelles

Lawrence M Kauvar

Stefan Ryser

Lauren Opremcak Bakaletz

Steven David Goodman

Reyna J Simon

Mikhail Gishizky

Michael Wittekind

Adam Vigil

Mohan Srinivasan

Matthew Paul Greving

Phung Tu Gip

Kevin Eduard Hauser

Cody A Moore

Alex T Taguchi

Christian Barrett

Andrew Morin

Jordan R Willis

Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.

Engineered CD25 polypeptides and uses thereof

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Binding moieties for biofilm remediation

Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.

Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling

Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HAmaturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.

Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof

Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.

Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3

Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HAmaturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Growing community of inventors

Belmont, CA, United States of America

Angeles Estelles